Specify a stock or a cryptocurrency in the search bar to get a summary
Chugai Pharmaceutical Co. Ltd.
CHGCFChugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd. Address: 2-1-1 Nihonbashi-Muromachi, Chuo, Japan, 103-8324
Analytics
WallStreet Target Price
880 914.46 JPYP/E ratio
33.5868Dividend Yield
1.2 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CHGCF
Dividend Analytics CHGCF
Dividend growth over 5 years
433 %Continuous growth
2 yearsPayout Ratio 5 years average
44 %Dividend History CHGCF
Stock Valuation CHGCF
Financials CHGCF
Results | 2019 | Dynamics |